Antiangiogenics and radiotherapy (Q37222791)

19 August 2017

1 reference

title

Antiangiogenics and radiotherapy (English)

1 reference

19 August 2017

0 references

2

Kaye J Williams

1 reference

19 August 2017

Aoife M Shannon

1

1 reference

19 August 2017

1 August 2008

1 reference

Journal of Pharmacy and Pharmacology

19 August 2017

1 reference

19 August 2017

60

1 reference

19 August 2017

8

1 reference

19 August 2017

1029-1036

1 reference

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).

19 August 2017

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Angiogenic tumor markers, antiangiogenic agents and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Suppression of tumor growth through disruption of hypoxia-inducible transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Endothelial cell survival and apoptosis in the tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Tumor angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Combined effects of angiostatin and ionizing radiation in antitumour therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

A sense of danger from radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Promises and pitfalls of anti-angiogenic therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Anti-angiogenic drugs: from bench to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Microenvironmental and cellular consequences of altered blood flow in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

HIF-1 and tumor progression: pathophysiology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Hypoxia-mediated regulation of gene expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Treatment resistance of solid tumors: role of hypoxia and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.8.0009

21 January 2018

Identifiers

DOI

10.1211/JPP.60.8.0009

1 reference

19 August 2017

1 reference

PubMed ID

18644195